NQ 304

Drug Profile

NQ 304

Latest Information Update: 16 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Antiplatelets; Vascular disorder therapies
  • Mechanism of Action Phosphotransferase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Thrombosis; Vascular disorders

Most Recent Events

  • 16 Feb 2006 No development reported - Preclinical for Vascular disorders in South Korea (unspecified route)
  • 26 Mar 2003 Preclinical trials in Vascular disorders in South Korea (unspecified route)
  • 26 Mar 2003 A preclinical study has been added to the Vascular Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top